ABO血型与卵巢癌患者预后的关系

摘要

目的 探讨ABO血型及其他相关因素对卵巢癌患者预后的影响.方法 回顾性分析天津医科大学肿瘤医院2007年12月—2011年7月采用根治性手术治疗的153例卵巢癌患者的临床病理资料和血型分布,其中A型血45例(29.4％)、B型血43例(28.1％)、O型50例(32.7％),AB型血15例(9.8％).分析不同血型患者临床特征的差异并对患者进行随访(末次随访时间2017年6月).采用Kaplan-Meier法绘制生存曲线,Log-rank法比较不同血型间总生存率及无病生存率的差异,Cox回归分析卵巢癌患者预后的影响因素.结果 (1)不同血型的患者年龄、月经情况、复发和转移、临床分期、CA-125水平以及辅助治疗等临床特征比较差异均无统计学意义(均P>0.05).(2)O型和B型血患者总生存率和无病生存率明显高于A型和AB型血患者(Log rankχ2分别为9.571、8.213,均P<0.05).Cox回归分析显示,ABO血型是卵巢癌患者预后的影响因素,AB型血的患者预后较差(B型vs.AB型HR=0.339,95％CI:0.138～0.830;O型vs.AB型HR=0.343,95％CI:0.137～0.855).结论 ABO血型与卵巢癌患者的生存状况相关,可用于评价卵巢癌患者的预后.%Objective To explore the influence of ABO blood type and other related factors on the prognosis in patients with ovarian cancer. Methods The clinical and pathological data and ABO blood types of 153 patients with ovarian cancer who were undergone radical surgery from December 2007 to July 2011 in Tianjin Medical University Cancer Institute and Hospital were retrospectively analyzed. Among them, there were 45 cases (29.4％) of blood type A, 43 cases (28.1％) of type B, 50 cases (32.7％) of type O, and 15 cases (9.8％) of type AB. The clinical characteristics of patients with different blood group types were analyzed, and the patients were followed up (the last follow-up time was June 2017). Kaplan-Meier method was used to draw the survival curve, and the Log-rank method was used to compare the differences between the total survival and disease-free survival rates in different blood groups. Cox regression analysis was performed to explore the prognostic factors in patients with ovarian cancer. Results (1) There were no statistically significant differences in the clinical features of different blood types, such as age, menstrual condition, recurrence, metastasis, clinical staging, CA-125 level, and adjuvant treatment (P>0.05). (2) The total survival rate and disease-free survival rate were significantly higher in patients of O and B blood types than those in patients of A and AB blood types (Log rank χ2=9.571 and 8.213 respectively, all P<0.05). Cox regression analysis showed that ABO blood group type was an influential factor in the prognosis of ovarian cancer patients, and patients with AB blood group showed a poorer prognosis (type B vs. type AB HR=0.339, 95％CI:0.138-0.830, type O vs. type AB HR=0.343, 95％CI:0.137-0.855). Conclusion ABO blood type is related to the survival of ovarian cancer patients, and which can be used to evaluate the prognosis in patients of ovarian cancer.